Huma receives world’s first and only multi-condition EU MDR Class IIb regulatory approval for its configurable SaMD disease management platform
(Adnkronos) – NEW YORK and LONDON, March 22, 2023 /PRNewswire/ — Huma Therapeutics (“Huma”), a leading global digital health company, today announced that it has become the only company in the world
